Monday, March 30
AI Stumbles and Pharma Bets
OpenAI's shutdown of Sora (opens in a new tab) exposes the harsh realities behind AI video generation, marking a potential inflection point for the entire sector. The company's decision reflects deeper technical challenges with scaling video AI safely and economically, while industry observers suggest this could signal broader cooling in AI video investments. Meanwhile, autonomous vehicles face their own AI limitations as Waymo robotaxis (opens in a new tab) continue struggling with basic safety protocols, requiring human intervention for emergency situations that should be algorithmic slam dunks.
Pharmaceutical giants are betting billions on AI-driven drug discovery as Insilico Medicine (opens in a new tab) lands a massive $2.75 billion collaboration with Eli Lilly. The partnership represents one of the largest AI-pharma deals to date, validating generative AI's potential to accelerate drug development timelines from decades to years. Separately, breakthrough treatments like Tazbentetol (opens in a new tab) for schizophrenia are showing promising results in phase 2 trials, with the compound targeting synaptic regeneration through novel fascin-1/F-actin pathway modulation.
Tech executives increasingly cite AI as justification for mass layoffs, creating a convenient narrative that shifts blame from strategic missteps to technological inevitability. This messaging coincides with growing concerns about AI systems inserting unwanted content, as developers report GitHub Copilot (opens in a new tab) injecting advertisements directly into code pull requests. The pattern suggests companies are using AI both as a shield for difficult decisions and struggling to maintain quality control as AI tools become more autonomous.